Hepatosteatozun Entekavir ve Tenofovir Tedavilerinde Virolojik Yanıta Etkisi

KORKMAZ P., DEMİRTÜRK N., BATIREL A., EREN TÜLEK N., özlüer m., harman r., ...More

klimik, vol.32, no.3, pp.265-274, 2019 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.5152/kd.2019.73
  • Journal Name: klimik
  • Journal Indexes: Other Indexes
  • Page Numbers: pp.265-274
  • Keywords: Fatty liver, entecavir, tenofovir, CHRONIC HEPATITIS-B, FATTY LIVER-DISEASE, VIRUS INFECTION, STEATOSIS, IMPACT, PREVALENCE, ANTIGEN, HOST
  • Bezmialem Vakıf University Affiliated: Yes

Abstract

Objective: Both chronic hepatitis B (CHB) and hepatosteatosis may lead to necroinflammation in liver. Therefore, the presence of hepatosteatosis might negatively affect the efficacy of antiviral therapy. We aimed to determine the effect of hepatosteatosis on virological response in patients with CHB receiving entecavir (ETV) and tenofovir (TDF) treatment.